Andrew Badrot, CEO at C² PHARMA recently stated that the pharmaceutical industry has responded extremely well to the coronavirus pandemic but that there will be no more ‘business as usual’ in pharmaceutical manufacturing after COVID-19.
TWENTYFOURSEVENBIOPHARMA